Endothelin-1 and functional tissue factor: A possible relationship with severity in primary pulmonary hypertension

Heart and Vessels

Volumn 18, Issue 1, 2003, Pages 12-17

  Collados, María T ^a,b   Velázquez, Blanca ^b   Borbolla, José R ^a   Sandoval, Julio ^b   Massó, Felipe ^b   Montaño, Luis F ^b   Guarner, Verónica ^b  

^a SCHOOL OF ENGINEERING AND SCIENCES   (Mexico)

^b INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

Author keywords

Endothelin 1; Endothelium; Primary pulmonary hypertension; Thrombosis; Tissue factor

Indexed keywords

BLOOD CLOTTING FACTOR; CHROMOGENIC SUBSTRATE; ENDOTHELIN 1; THROMBOMODULIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ARTICLE; CELL FUNCTION; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE SEVERITY; ENZYME IMMUNOASSAY; HEMODYNAMICS; HUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; THROMBOSIS; VASCULAR ENDOTHELIUM; VASOCONSTRICTION;

ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION, PULMONARY; LIPOPROTEINS; PROGNOSIS; THROMBOMODULIN; THROMBOPLASTIN; VON WILLEBRAND FACTOR;

EID: 0348198462     PISSN: 09108327     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003800300002     Document Type: Article

References (37)

1. Thomson JR, Trembath RC (2000) Primary pulmonary hypertension: the pressure rises for a gene. J Clin Pathol 53:899-903
2. Rich S (1988) Primary pulmonary hypertension. Prog Cardiovasc Dis 31:205-238
3. Loscalzo J (1992) Endothelial dysfunction in pulmonary hypertension. N Engl J Med 237:117-119
4. Pietra GG, Edwards WD, Kay MJ, Rich S, Kerns J, Schloo B, Ayres SM, Bergofsky EH, Brundage BM, Detre KM, Fishman AP, Goldring RM, Groves BM, Levy PS, Reid LM, Vreim CE, Williams GW (1989) Histopathology of PPH. Circulation 80:1198-1206
5. Wanstall JC, Jeffery TK (1998) Recognition and management of pulmonary hypertension. Drugs 56:989-1007
6. Rich S, Brundage BH (1989) Pulmonary hypertension: a cellular basis for understanding the pathophysiology and treatment. J Am Coll Cardiol 14:545-601
7. Hassell KL (1998) Altered hemostasis in pulmonary hypertension. Blood Coag Fibrinol 9:107-117
8. Rabinovitch M, Andrew M, Thom H, Trusler GA, Williams WG, Rowe RD, Olley PM (1987) Abnormal endothelial factor VIII associated with pulmonary hypertension and congenital heart defects. Circulation 76:1043-1052
9. Lopes AA, Maeda NY, Aiello VD, Ebaid M, Bydlowski SP (1993) Abnormal multimeric and oligomeric composition is associated with enhanced endothelial expression of von Willebrand factor in pulmonary hypertension. Chest 104:1455-1460
10. Cacoub P, Dorent R, Maistre G, Carayon A, Riquet M, Noe E, Piette JC, Godeau P, Gandjbakhch I (1997) Endothelin-1 in the lungs of patients with pulmonary hypertension. Cardiovasc Res 33:196-200
11. Cacoub P, Karmochkine M, Dorent R, Nataf P, Piette JC, Godeau P, Gandjbakhch I, Boffa MC (1996) Plasma levels of thrombomodulin in pulmonary hypertension. Am J Med 101:160-164
12. Lopes AA, Maeda NY (1998) Circulating von Willebrand factor antigen as a predictor of short term prognosis in pulmonary hypertension. Chest 114:1276-1282
13. Collados MT, Sandoval J, López S, Massó F, Páez A, Borbolla JR, Montaño LF (1999) Characterization of von Willebrand factor in primary pulmonary hypertension. Heart Vessels 14:246-252
14. Sandoval J, Bauerle O, Palomar A, Gómez A, Martínez-Guerra ML, Beltrán M, Guerrero L (1994) Survival in primary pulmonary hypertension. Circulation 89:1733-1744
15. Rich S (1993) Primary pulmonary hypertension. Curr Opin Cardiol 8:796-801
16. Grossmann R, Babin-Ebell J, Mishop M, Schwender S, Neukam K, Hickethier T, Elert O, Keller F (1996) Changes in coagulation and fibrinolytic parameters caused by extracorporeal circulation. Heart Vessels 11:310-317
17. Fishman AP (1998) Etiology and pathogenesis of primary pulmonary hypertension. Chest 114:242S-247S
18. Rich S, Kaufman E, Levy PS (1992) The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327:76-81
19. Stewart DJ, Levy RD, Cernacek P, Langleben D (1991) Increase plasma endothelin 1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 114:464-469
20. Schmitz-Spanke S, Schipke JD (2000) Potential role of endothelin-1 and endothelin antagonists in cardiovascular disease. Basic Res Cardiol 95:290-298
21. Salomone OA, Elliott PM, Calvino R, Holt D, Kaski JC (1996) Plasma immunoreactive endothelin concentration correlates with severity of coronary artery disease in patients with stable angina pectoris and normal ventricular function. J Am Coll Cardiol 28:14-19
22. Kiely DG, Cargill RI, Strughers AD, Lipworth BJ (1997) Cardiopulmonary effects of endothelin-1 in man. Cardiovasc Res 33:378-386
23. Cucurull E, Ghavari AE (1997) Thrombomodulin: a new frontier in lupus research? Clin Exp Rheumatol 15:1-4
24. Gando S, Kameue T, Nanzaki S, Nakanishi Y (1995) Cytokines, soluble thrombomodulin and disseminated intravascular coagulation in patients with systemic inflammatory response syndrome. Thromb Res 80:519-526
25. Tanaka A, Ishii H, Hiraishi S, Kazama M, Maezawa H (1991) Increased thrombomodulin values in plasma of diabetic men with microangiopathy. Clin Chem 37:269-272
26. Takahashi H, Hanano M, Wada K, Tatewaki W, Niwano H, Tsubouchi J, Nakano M, Nakamura T, Shibata A (1991) Circulating thrombomodulin in thrombotic thrombocytopenic purpura. Am J Hematol 38:174-177
27. Tsukada N, Matsuda M, Miyagi K, Yanagisawa N (1995) Thrombomodulin in the sera of patients with multiple sclerosis and human lymphotropic virus type-1-associated myelopathy. J Neuroimmunol 56:113-116
28. Morrisey JH (2001) Tissue factor and factor VII initiation of coagulation. In: Colman RW, Hirsch J, Marder VJ, Clowes AW, George JN (eds) Hemostasis and thrombosis. Lippincott Williams & Wilkins, Philadelphia, pp 89-101
29. Crawley J, Lupu F, Westmuckett AD, Severs NJ, Kakkar VV, Lupu C (2000) Expression, localization, and activity of tissue factor pathway inhibitor in normal and atherosclerotic human vessels. Arterioscl Thromb Vasc Biol 20:1362-1382
30. Giesen PL, Nemerson Y (2000) Tissue factor in the loose. Semin Thromb Hemost 26:379-384
31. Takahashi H, Satoh N, Wada K, Takakuwa E, Seki Y, Shibata A (1994) Tissue factor in plasma of patients with disseminated intravascular coagulation. Am J Hematol 46:333-337
32. Koyama T, Nishida K, Ohdama S, Sawada M, Murokami N, Hirosawa M, Kuriyama R, Matsuzawa K, Hasegawa R, Aoki N (1994) Determination of plasma tissue factor antigen and its clinical significance. Br J Haematol 87:343-347
33. Koyama T, Ohdama S, Aoki N (1997) Plasma tissue factor reflects endothelial cell injury rather than upregulation of tissue factor expression. Thromb Haemost 78:972
34. Okuwaga Y, Wada H, Noda T, Sakakura M, Nakasaki T, Watanabe R, Deguchi H, Gabazza EC, Mori Y, Nishikawa M, Deguchi K, Nobori T, Shiku H (2000) Increased plasma levels of tissue factor pathway inhibitor activated factor X complex in patients with disseminated intravascular coagulation. Am J Hematol 65:210-214
35. Asakura H, Ontachi Y, Mizutani T, Kato M, Saito M, Morishita E, Yamazaki M, Suga Y, Takami A, Miyamoto K, Nakao S (2001) Elevated levels of free tissue factor pathway inhibitor antigen in cases of disseminated intravascular coagulation caused by various underlying diseases. Blood Coagul Fibrinolysis 12:1-8
36. Grabowski EF, Reininger AJ, Petteruti PG, Tsukurov O, Orkin RW (2001) Shear stress decreases endothelial cell tissue factor activity by augmenting secretion of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 21:157-162
37. Westmuckett AD, Lupu C, Roquefeuil S, Krausz T, Kakker VV, Lupu F (2000) Fluid flow induces upregulation of synthesis and release of tissue factor pathway inhibitor in vitro. Arterioscler Thromb Vasc Biol 11:2474-2482